Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer

Abstract Background Prognosis and treatment options differ for each molecular subtype of breast cancer, but risk of regional lymph node (LN) metastasis for each subtype has not been well studied. Since LN status is the most important predictor for prognosis, the aim of this study is to investigate t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of surgical research 2013-12, Vol.185 (2), p.697-703
Hauptverfasser:	Howland, Nicholas K., MD, Driver, Teryn D., BS, Sedrak, Michael P., MD, Wen, Xianfeng, MD, Dong, Wenli, MS, Hatch, Sandra, MD, Eltorky, Mahmoud A., MD, PhD, Chao, Celia, MD, FACS
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor - metabolism Breast Neoplasms - classification Breast Neoplasms - epidemiology Breast Neoplasms - secondary Female Humans Immunohistochemistry Immunohistochemistry - methods Ki-67 Antigen - metabolism Logistic Models Lymphatic Metastasis - pathology Middle Aged Molecular subtypes of breast cancer Multivariate Analysis Predictive Value of Tests Prognosis Receptor, Epidermal Growth Factor - metabolism Receptor, ErbB-2 - metabolism Retrospective Studies Risk Factors Surgery Triple Negative Breast Neoplasms - classification Triple Negative Breast Neoplasms - epidemiology Triple Negative Breast Neoplasms - secondary
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background Prognosis and treatment options differ for each molecular subtype of breast cancer, but risk of regional lymph node (LN) metastasis for each subtype has not been well studied. Since LN status is the most important predictor for prognosis, the aim of this study is to investigate the propensity for LN metastasis in each of the five breast cancer molecular subtypes. Methods Under an institutional review board–approved protocol, we retrospectively reviewed the charts of all pathologically confirmed breast cancer cases from January 2004 to June 2012. Five subtypes were defined as luminal A (hormone receptor positive, Ki-67 low), luminal B (hormone receptor positive, Ki-67 high), luminal human epidermal growth factor receptor 2 (HER2), HER2-enriched (hormone receptor negative), and triple negative (TN). Results A total of 375 patients with complete data were classified by subtype: 95 (25.3%) luminal A, 120 (32%) luminal B, 69 (18.4%) luminal HER2, 26 (6.9%) HER2-enriched, and 65 (17.3%) TN. On univariate analysis, age (
ISSN:	0022-4804 1095-8673
DOI:	10.1016/j.jss.2013.06.048